We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Is the GlaxoSmithKline share price a bargain or should I buy this high-yielding small-cap?

Does this small-cap share’s recovery potential outshine the forward prospects of GlaxoSmithKline plc (LON: GSK)?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The share price of Vertu Motors (LSE: VTU) continued its slide today on the release of interim results. The automotive retailer has a network of 125 sales and aftersales outlets across the UK and the shares are down around 22% since the end of August.

Today’s figures show that revenue increased by around 7.6% compared to the equivalent period last year, but adjusted earnings per share fell by 8%. There’s nothing the stock market hates more than falling earnings, so I think we’ve found the reason for the weakness in the share price. The directors held the interim dividend firm at last year’s level.

XXX

Big acquisition

In July, towards the end of the period, the company spent almost £22m acquiring Hughes Group Holdings Limited, which came with a “significant Mercedes-Benz presence in the M4/M40 corridor.” I think that’s a bold move with so many economic uncertainties on the horizon. The balance sheet was weakened and the firm reported net debt on 31 August of £8.7m, which compares to a net cash position of £20.8m the year before.

Car dealership businesses are notoriously cyclical and when trading conditions have been good and profitable, I reckon it makes sense for them to build up their cash reserves so that they can survive the next downturn in the economy. Indeed, the current trading and outlook statement is a little murky and highlights several risks.

The company said that supply-side issues in the new car market led to declining volumes with September registrations being the lowest since 2011.” September trading was affected by Worldwide Harmonised Light Vehicle Test Procedure (WLTP) emissions regulations across the European Union. Meanwhile, car margins are under pressure because the depressed level of Sterling is affecting manufacturers’ profitability. The firm reckons some supply issues are “likely to continue into early 2019.”

Give me steady demand

Demand for cars is holding up for the time being but the directors admit that political uncertainty in the UK could lead to consumer uncertainty and volatility for the rest of the firm’s trading year. The company goes on to list a number of positives, but the stock market looks wary of the stock to me. And I share the market’s concerns. Despite the firm’s high-looking dividend yield and substantial asset backing from the property it owns, I think the shares are vulnerable to downside shocks, so I’d rather invest in a less cyclical firm such as pharmaceutical outfit GlaxoSmithKline (LSE: GSK).

One of the main attractions of the firm to me is that its pharmaceutical business resides at the opposite end of the defensive/cyclical scale from Vertu Motors. Unlike big-ticket purchases such as cars, people keep buying their medicines whatever the economic climate and such reliable repeat-purchasing tends to lead to consistent cash inflows.

On top of that, GlaxoSmithKline is paying a bigger dividend than Vertu Motors anyway. The recent share price close to 1,487p throws up a tempting forward yield of 5.4% for 2019. I think that GlaxoSmithKline is recovering well from a period of declining earnings as previously best-selling drugs lost their patent protection. I’d rather take my chances with the firm’s forward prospects than with the uncertain outlook of a cyclical firm such as Vertu Motors.

Kevin Godbold has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Vertu Motors. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Friends and sisters exploring the outdoors together in Cornwall. They are standing with their arms around each other at the coast.
Investing Articles

£503 buys 14 shares in this FTSE 250 stock that returned 23.9% annually for the last 15 years

This FTSE 250 stock has averaged a huge return for 15 years. At today's price, £503 buys 14 shares. But…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

£1,000 buys 25 shares in this FTSE 100 stock that’s returned 29.2% annually for the last 10 years

This FTSE 100 mining stock has returned close to 30% a year for a decade. At 3,995p, £1,000 buys 25…

Read more »

Female student sitting at the steps and using laptop
Investing Articles

Down 47%, is this growth stock finally worth buying in May?

With a £288m order book and a hidden pipeline of defence and nuclear contracts, is this growth stock now too…

Read more »

House models and one with REIT - standing for real estate investment trust - written on it.
Investing Articles

2 REITs yielding 7%+ to consider for passive income in 2026

A REIT backed by the NHS and another backed by Tesco and Sainsbury's with both yielding 7%+. Here's why I'm…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

Just 97 shares of this UK dividend stock generate £238 in passive income

A 5.7% yield, £238 in passive income from just 97 shares, and one of the most divisive dividend stocks on…

Read more »

ISA coins
Investing Articles

£10,000 in an ISA generates a second income of…

The London Stock Exchange is home to some of the world's most generous dividends. But how big a second income…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

Expert recommendations: 2 top income stocks yielding 7%+!

With yields of 7.2% and 7.8% respectively, these two income stocks are catching the eyes of institutional analysts. Should investors…

Read more »

Illustration of flames over a black background
Investing Articles

3 top income-focused stocks to buy in May 2026, according to experts

Looking for a stock to buy for income in May 2026? Experts have flagged these three UK dividend shares as…

Read more »